Baird served as lead manager on the offering
AboutAssembly Biosciences, Inc. (“Assembly”) (NASDAQ:ASMB) recently completed a follow-on offering of 4,000,000 shares of common stock plus an additional 600,000 shares from the exercise of the over-allotment option at a price to the public of $36.00 per share raising gross proceeds of $166 million. Assembly intends to use the net proceeds from the sale of the common stock to fund clinical trials, nonclinical studies, research and development and for general corporate purposes.
Assembly Biosciences, Inc. is a clinical-stage public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutic candidates for the treatment of hepatitis B virus infection and a microbiome program developing novel oral synthetic live biotherapeutic candidates for disorders associated with the microbiome. Assembly’s HBV-cure program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. Assembly’s microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patented delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is headquartered in Carmel, Indiana.
CONTACT US TO LEARN MORE
- July 2018
- Assembly Biosciences, Inc.
- Target Location
- North America